Cases & Deals

Sanofi, Orano Med, and RadioMedix collaborate to develop radioligand therapies

Client(s) Sanofi

Jones Day represented and supported Sanofi's in-house team in connection with an exclusive licensing agreement with RadioMedix, Inc., and Orano Med, subsidiary of the Orano Group. This collaboration between Sanofi, RadioMedix, and Orano Med focuses specifically on the late-stage project, AlphaMedix™ (212Pb-DOTAMTATE), being evaluated for the treatment of adult patients with somatostatin-receptor expressing neuroendocrine tumors (NETs), a rare cancer. Under the licensing agreement, Sanofi will be responsible for the global commercialization of AlphaMedix™, while Orano Med will be responsible for the manufacturing of AlphaMedix™ through its global industrial platform currently under development. Under the terms of the agreement, RadioMedix and Orano Med will receive an upfront payment of €100 million and up to €220 million in sales milestones and be eligible for tiered royalties.